Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Gilead Sciences Inc (GILD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 96,384,408
  • Shares Outstanding, K 1,306,730
  • Annual Sales, $ 30,390 M
  • Annual Income, $ 13,501 M
  • 36-Month Beta 1.21
  • Price/Sales 3.16
  • Price/Cash Flow 5.83
  • Price/Book 4.59

Price Performance

See More
Period Period Low Period High Performance
1-Month
68.29 +8.01%
on 06/22/17
74.41 -0.87%
on 07/21/17
+6.26 (+9.27%)
since 06/21/17
3-Month
63.76 +15.68%
on 06/16/17
74.41 -0.87%
on 07/21/17
+7.83 (+11.88%)
since 04/21/17
52-Week
63.76 +15.68%
on 06/16/17
88.85 -16.98%
on 07/25/16
-13.48 (-15.45%)
since 07/21/16

Most Recent Stories

More News
Is a Beat in the Cards for Vertex (VRTX) in Q2 Earnings?

Impressive performance of Vertex Pharmaceuticals' (VRTX) cystic fibrosis drugs Kalydeco and Orkambi may drive the stock to an earnings beat in Q2.

CELG : 137.74 (+1.05%)
PTI : 3.51 (-3.70%)
VRTX : 163.17 (+2.41%)
GILD : 73.76 (+0.46%)
Watch for Gilead Sciences to Potentially Pullback After Gaining 1.12% Yesterday

Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $73.28 to a high of $74.41. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of...

GILD : 73.76 (+0.46%)
Watch for Gilead Sciences to Potentially Pullback After Gaining 1.12% Yesterday

Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $73.28 to a high of $74.41. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of...

GILD : 73.76 (+0.46%)
What to Expect from Keryx (KERX) this Earnings Season?

Keryx Biopharmaceuticals, Inc. (KERX) intends to focus on the growth of Auryxia in the U.S. dialysis market. The company is also making efforts for label expansion on Auryxia in the iron-deficiency anemia...

AGEN : 5.05 (+0.40%)
KERX : 7.24 (+2.40%)
GILD : 73.76 (+0.46%)
ICPT : 127.40 (-0.98%)
What's in the Offing for Bristol-Myers (BMY) in Q2 Earnings?

Bristol-Myers Squibb Company (BMY) is scheduled to report first-quarter 2017 results on Jul 27, before the opening bell. Last quarter, the company beat earnings estimates by 16.7%.

MRK : 62.63 (-0.49%)
VRTX : 163.17 (+2.41%)
GILD : 73.76 (+0.46%)
BMY : 55.65 (+0.38%)
HCA Healthcare (HCA) Q2 Earnings: Will it Beat Estimates?

HCA Healthcare's (HCA) second-quarter earnings are likely to witness equivalent, admission growth and accretion from a number of acquisitions. Commercial business will likely be a dampener.

CELG : 137.74 (+1.05%)
HCA : 85.73 (-0.03%)
GILD : 73.76 (+0.46%)
PFE : 33.48 (-0.18%)
Amgen (AMGN) to Report Q2 Earnings: What's in the Cards?

While Amgen, Inc.'s (AMGN) growth drugs like Prolia & Xgeva might continue to do well. Biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.

CELG : 137.74 (+1.05%)
NVS : 84.99 (-0.50%)
GILD : 73.76 (+0.46%)
AMGN : 180.21 (+0.50%)
Is a Beat in Store for Alexion (ALXN) this Earnings Season?

Alexion Pharmaceuticals, Inc.'s (ALXN) drugs like Soliris and Strensiq have been performing well. Let's see if these lead the company to an earnings beat.

AGEN : 5.05 (+0.40%)
GILD : 73.76 (+0.46%)
ICPT : 127.40 (-0.98%)
ALXN : 131.79 (+1.53%)
Is Gilead (GILD) Poised for a Beat This Earnings Season?

Strong performance by HIV and other antiviral products is likely to drive Gilead Sciences Inc.'s (GILD) second-quarter 2017 results.

VRTX : 163.17 (+2.41%)
ABBV : 74.63 (+0.84%)
GILD : 73.76 (+0.46%)
ALXN : 131.79 (+1.53%)
Gilead's HCV Portfolio Receives a Boost With Vosevi Approval

Gilead's (GILD) HCV portfolio received a boost with the FDA's approval of its once-daily HCV regimen, Vosevi.

JNJ : 135.31 (-0.92%)
ABBV : 74.63 (+0.84%)
GILD : 73.76 (+0.46%)
BMY : 55.65 (+0.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections...

See More

Support & Resistance

2nd Resistance Point 74.95
1st Resistance Point 74.35
Last Price 73.76
1st Support Level 73.22
2nd Support Level 72.69

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.